INSIGHTS ON CLINICAL TRIAL DESIGN

• What Can Healthy Participants Tell Us In Early Immuno-oncology Development?

  Healthy participants may help answer early immuno-oncology questions when targets, endpoints, and risks align. Human data shows where this approach works and where it doesn’t.

• Winning Enrollment In A Competitive CNS Trial Landscape

  Many CNS trials today operate in a highly competitive environment. Enrollment success is shaped by the decisions teams make under these constraints.

• Digital Twins: From Protocol Design to Predictive Study Execution

  A growing generation of AI-enabled digital twin approaches offers a new path. Instead of treating the protocol as a static document, organizations can model it as a dynamic system.

• FDA Psychedelic Drug Guidance: What Sponsors Need To Know

  FDA's July 2026 final guidance on psychedelic drug clinical investigations sets expectations for sponsors developing psilocybin, LSD, and MDMA therapies. Learn what it means for your program.

• The Scoop On The SCOPE Summit

  2/19/2025

  From industry partnerships to patient recruitment to proprietary data, SCOPE 2025 was packed with informational sessions.

• Accelerating A Schizophrenia Trial While Ensuring Quality

  7/31/2026

  Tight timelines and rising patient targets don't have to derail a trial. See how speed and data quality can work together from enrollment to database lock.

• De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital

  9/3/2025

  For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.

• The True Science Behind eCOA, Shaped By Patient And Site Insights

  6/17/2026

  This webinar brings together patients, sites, and eCOA science to dismantle the researcher-subject hierarchy and replace it with a collaborative model.

• Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems

  10/7/2025

  Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.